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Conclusions: Amiodarone reduces the risk of SCD by 29% in
patients with ischemic/nonischemic cardiomyopathy, but
has a neutral effect on all-cause mortality.
Perspective: This meta-analysis reminds us that amiodarone
is not an adequate substitute for an implantable car-
dioverter-defibrillator (ICD) when the goal is to improve
survival in patients with a cardiomyopathy. Consistent with
these results, the American College of Cardiology/American
Heart Association/European Society of Cardiology guide-
lines recommend the use of amiodarone for prevention of
SCD only in high-risk patients who do not qualify for an
ICD (e.g., patients with class IV heart failure or life-
expectancy <1 year).  
Summary written by: Fred Morady, MD
Syncope and Risk of Sudden Death in
Hypertrophic Cardiomyopathy
Spirito P, Autore C, Rapezzi C, et al.
Circulation 2009;119:1703-1710.
Study Design: What are the prognostic implications of syncope
in patients with hypertrophic cardiomyopathy (HCM)?
Methods: This was a retrospective review of 1,511 consecutive
patients (mean age 46 years) with HCM evaluated at six refer-
ral centers in 1983-2006. Mean follow-up was 5.6 years.
Results: During initial evaluation, 153 patients (10%) had a
history of unexplained syncope and 52 patients (3.4%) had a
history of neurocardiogenic syncope. Incidence of sudden car-
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Arrhythmias
Amiodarone for the Prevention of Sudden Cardiac
Death: A Meta-Analysis of Randomized Controlled
Trials
Piccini JP, Berger JS, O’Connor CM.
Eur Heart J 2009;Mar 31:[Epub ahead of print].
Study Design: Does amiodarone prevent sudden cardiac death
(SCD)?
Methods: This meta-analysis of 15 trials randomized patients
with ischemic or nonischemic cardiomyopathy to treatment
with amiodarone (n = 4,260) or placebo (n = 4,262). Mean
age ranged from 57 to 68 years, mean ejection fraction from
18% to 44%, and mean duration of follow-up was 1.7 years.
The most frequently used maintenance dose of amiodarone
was 200 mg/day.
Results: The prevalence of SCD was significantly lower in
the amiodarone group (7.1%) than in the control group
(9.7%). However, all-cause mortality in the amiodarone
group was 18.1% and did not differ significantly from the
19.6% rate of all-cause mortality in the control group.
Adverse effects that were significantly more common in the
amiodarone group were pulmonary toxicity (2.9% vs. 1.5%,
respectively), thyroid toxicity (3.6% vs. 0.4%), hepatic toxic-
ity (1.8% vs. 0.7%), and bradycardia (2.8% vs. 1.5%). The
drug discontinuation rate was significantly higher in the
amiodarone group (32%) than placebo (21%).
received a CRT-D. Compared to when the implanter was
an electrophysiologist, eligible patients were 7% less likely to
receive a CRT-D with cardiologists and 19% less likely with
thoracic surgeons. Among ICDs implanted by non-electro-
physiologists, 64% were implanted at hospitals that had an
electrophysiologist on staff.
Conclusions: Compared to non-electrophysiologists, electro-
physiologists have a lower complication rate for ICD
implantation and are more likely to implant a CRT-D in
eligible patients.
Perspective: There is clear-cut evidence of underutilization of
ICDs in the United States, but no evidence that this stems
from a shortage of electrophysiologists or local unavailability
of an electrophysiologist. With the mean distance between
hospitals with and without electrophysiologists being only
22 miles, it is difficult to argue that convenience to patients
is adequate justification for suboptimal outcomes when
ICDs are implanted by non-electrophysiologists.  
Summary written by: Fred Morady, MD
Cardiovascular Surgery
Acute Kidney Injury After Cardiac Surgery: Focus
on Modifiable Risk Factors
Karkouti K, Wijeysundera DN, Yau TM, et al.
Circulation 2009:119:495-502.
Study Design: What are the risk factors for development of
acute kidney injury (AKI) after cardiac surgery?
Methods: This was a multicenter observational analysis of 3,500
adult patients undergoing cardiac surgery at seven hospitals.
The three thresholds of AKI identified included a >25%
decrease in glomerular filtration rate (GFR), >50% decrease in
GFR, and >75% decrease in GFR, estimated with the
Cockcroft-Gault equation. Multivariate logistic regression
modeling was used to determine independent relationships
between the three thresholds of AKI and preoperative and
modifiable risk factors.
Results: The three thresholds of AKI occurred in 24%, 7%, and
3% of the cohort, respectively. These were independently
associated with a greater than fourfold adjusted odds ratio for
death in the perioperative period. Multiple perioperative vari-
ables, correlated with the development of AKI, included
nonmodifiable factors such as preoperative intra-aortic balloon
pump, urgent surgery, and prolonged cardiopulmonary bypass.
Use of aprotinin was also found to be weakly independently
associated with AKI. Modifiable variables identified for strong
independent association with AKI included presence of preop-
erative anemia, and need for re-exploration and perioperative
red blood cell transfusion (all p < 0.0001).
diac death (SCD) was 0.9%/year; 6% had an ICD. Compared
to patients without syncope, patients with unexplained syn-
cope had a 78% higher risk of SCD and patients with
neurocardiogenic syncope did not have a higher risk. Among
29 patients with a history of syncope and an ICD, 14% had
appropriate ICD therapies. Unexplained syncope was associ-
ated with an eightfold higher risk of SCD in patients <18
years of age. Syncope within 6 months of evaluation was asso-
ciated with a fivefold higher risk of SCD, but syncope >5
years before evaluation was not a risk factor. The risk of SCD
in patients with recent unexplained syncope was highest
(29%/year) in patients <18 years of age.
Conclusions: Unexplained syncope is a risk factor for SCD in
patients with HCM, particularly when relatively recent, and
in patients under the age of 18 years.
Perspective: Most guidelines recommend an ICD for patients
with HCM who have either a family history of SCD, wall
thickness >30 mm, nonsustained ventricular tachycardia, or
unexplained syncope. The present study refines the guide-
lines by indicating that unexplained syncope may not
mandate an ICD in older patients if it occurred >5 years
before evaluation.  
Summary written by: Fred Morady, MD
Association of Physician Certification and
Outcomes Among Patients Receiving an
Implantable Cardioverter-Defibrillator
Curtis JP, Luebbert JJ, Wang Y, et al.
JAMA 2009;301:1661-1670.
Study Design: Do the outcomes of implantable cardioverter
defibrillator (ICD) implantation differ between electrophysi-
ologists and non-electrophysiologists?
Methods: This was a retrospective analysis of data from
111,293 ICD implants submitted between January 2006 and
June 2007 to the ICD Registry, part of the National
Cardiovascular Data Registry of the American College of
Cardiology partnering with the Heart Rhythm Society.
Implanting physicians were classified as electrophysiologists,
cardiologists, thoracic surgeons, or other specialists.
Outcomes included the complication rate and percentage of
patients qualifying for a biventricular ICD (CRT-D) who
received that device.
Results: Twenty-nine percent of ICDs were implanted by
non-electrophysiologists. The rates of total and major com-
plications were lowest among electrophysiologists (3.5% and
1.3%, respectively) and highest among thoracic surgeons
(5.8% and 2.5%, respectively). Compared to electrophysiolo-
gists, the overall risk of a complication was 11% higher with
cardiologists and 44% higher with thoracic surgeons.
Among electrophysiologists, 83% of eligible patients




RAAA repair. Higher elective EVAR as well as RAAA vol-
ume increased the mortality advantage for EVAR.
Perspective: I believe that in the short-term, we will finally,
after decades of open surgery for RAAA, see a decrease in
mortality associated with RAAA. I am sure that this
approach may not have the same long-term success as elec-
tive EVAR, and that many more secondary procedures,
including graft explants, will be required. However, having
performed a number of open and EVAR for RAAA, we
should if anatomically feasible perform EVAR for RAAA. 
Summary written by: Gilbert Upchurch, Jr., MD
General Cardiology
Long-Term Outcome of Prophylactic Coronary
Revascularization in Cardiac High-Risk Patients
Undergoing Major Vascular Surgery (from the
Randomized DECREASE-V Pilot Study)
Schouten O, van Kuijk JP, Flu WJ, et al., on behalf of the DECREASE
Study Group.
Am J Cardiol 2009;103:897-901.
Study Design: What is the long-term outcome after prophy-
lactic coronary revascularization prior to major vascular
surgery in high-risk patients?
Methods: The authors reported on data from the
DECREASE-V trial, in which patients at clinically high risk
(≥3 risk factors and stress-induced myocardial ischemia on
testing) and undergoing vascular surgery were randomized to
best medical therapy versus best medical therapy plus preoper-
ative coronary revascularization. For the current study,
outcomes assessed were long-term all-cause mortality and
combined endpoint of all-cause mortality, nonfatal MI, and
coronary revascularization during follow-up.
Results: Of 1,880 patients scheduled for major vascular sur-
gery, 430 had ≥3 risk factors, of whom 101 had extensive
ischemia on stress testing and were randomized to revascular-
ization (n = 49) or no revascularization (n = 52). After
follow-up of 2.8 years, the overall survival rate was 64% for
patients in the no revascularization group versus 65% in
patients who underwent revascularization (hazard ratio [HR],
1.18; 95% CI, 0.63-2.19; p = 0.61). Rate of the combined
endpoint was 49% versus 42% for medical treatment versus
coronary revascularization, respectively (HR, 1.51; 95% CI,
0.89-2.57; p = 0.13).
Conclusions: Preoperative coronary revascularization in high-
risk patients undergoing major vascular surgery was not
associated with improved postoperative or long-term out-
come compared with best medical treatment alone.
Conclusions: AKI after cardiac surgery is prevalent; several
potentially modifiable variables may diminish the risk for
AKI after cardiac surgery.
Perspective: The most important modifiable variable, I
believe, is use of red blood cell transfusions. While transfu-
sions may be lifesaving in multiple clinical situations,
significantly more data are demonstrating the contribution of
transfusion to development of organ injury, likely related to
the changes in red blood cells that occur during storage.
Also, there appears to be a weak association with the use of
aprotinin and postoperative renal dysfunction in this study.
With the recent withdrawal of this drug from the market,
this study adds to evidence suggesting increasing renal failure
with the use of aprotinin. 
Summary written by: Himanshu J. Patel, MD
Endovascular Treatment of Ruptured Abdominal
Aortic Aneurysms in the United States (2001-
2006): A Significant Survival Benefit Over Open
Repair Is Independently Associated With Increased
Institutional Volume
McPhee J, Eslami MH, Arous EJ, Messina LM, Schanzer A.
J Vasc Surg 2009;49:817-826.
Study Design: What are the national outcomes after endovas-
cular aneurysm repair (EVAR) for ruptured abdominal aortic
aneurysm (RAAA)?
Methods: The Nationwide Inpatient Sample was used to iden-
tify patients treated with open or EVAR for RAAA between
2001 and 2006. Procedure volume was determined for each
institution categorizing hospitals as low-, medium-, and high-
volume, with the primary outcome variable being in-hospital
mortality.
Results: A total of 27,750 hospital discharges for RAAA
occurred, with 11.5% (3,179) treated with EVAR. While
overall RAAA rates remained constant, EVAR utilization
increased over time (5.9% in 2001 to 18.9% in 2006). EVAR
had a lower overall in-hospital mortality than open repair
(31.7% vs. 40.7%). On multivariable regression, open repair
was an independent predictor of mortality (odds ratio [OR],
1.56; 95% confidence interval [CI], 1.29-1.89). The use of
EVAR increased with age (>80 years) (OR, 1.58; 95% CI,
1.30-1.93), high elective EVAR volume (>40/year) versus
medium (19-40/year) (OR, 2.65; 95% CI, 1.86-3.78), and
low (<19/year) (OR, 5.37; 95% CI, 3.60-8.0). EVAR for
RAAA had a shorter length of stay (11.1 vs. 13.8 days),
higher rates of discharge to home (65.1% vs. 53.9%), and
lower charges ($108,672 vs. $114,784).
Conclusions: This is the first national study to document that
EVAR has a lower postoperative mortality than open
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Perspective: This study provides further evidence of the limi-
tations of coronary revascularization in altering outcomes for
patients with coronary artery disease. The current study,
combined with the CARP study, suggests that finding coro-
nary disease and revascularizing it in stable patients provides
no perioperative or long-term benefit. We should resist the
temptation to resolve ischemia found on stress testing, and
focus on therapy that will improve outcomes. This suggests
a significantly reduced role for perioperative coronary revas-
cularization and stress testing to search for ischemia. 
Summary written by: James B. Froehlich, MD 
Long-Acting Calcium Antagonists in Patients With
Coronary Artery Disease: A Meta-Analysis
Bangalore S, Parkar S, Messerli FH.
Am J Med 2009;122:356-365.
Study Design: Do long-acting calcium antagonists reduce car-
diovascular disease outcomes among patients with coronary
artery disease (CAD)?
Methods: The investigators conducted a meta-analysis of 15
studies narrowed from a literature search encompassing
years 1966 to 2008, of 654 studies, of which 100 were ran-
domized controlled trials. Inclusion criteria were
randomized controlled study design, comparison of long-
acting calcium channel blockers (CCBs) with other agents
(including placebo), patients with CAD, and follow-up of at
least 1 year. Outcomes were all-cause mortality, cardiovas-
cular disease mortality, nonfatal myocardial infarction,
stroke, angina pectoris, and heart failure.
Results: From the 15 trials, 47,694 patients fulfilled the
inclusion criteria, with a mean follow-up of 2.6 years. In 10
trials, CCBs were compared to placebo, and in five trials,
the CCBs were compared to other antihypertensive agents.
CCBs had no association with increased risk for all-cause
mortality (relative risk [RR], 0.99; 95% CI, 0.94-1.05), car-
diovascular mortality (RR, 1.03; 95% CI, 0.95-1.11),
nonfatal myocardial infarction (RR, 0.96; 95% CI, 0.87-
1.06), or heart failure (RR, 0.86; 95% CI, 0.71-1.05). A
reduction in stroke was observed for use of CCBs (RR,
0.79; 95% CI, 0.70-0.89). A reduction in angina pectoris
was also observed (RR, 0.82; 9% CI, 0.72-0.94). When
compared with placebo, a significant reduction (28%, p <
0.001) in heart failure was observed.
Conclusions: Among patients with CAD, long-acting CCBs
(either dihydropyridines or nondihydropyridines) were asso-
ciated with reductions in risk of stroke, angina, and heart
failure.
Perspective: These data suggest that the use of long-acting
CCBs may be an appropriate alternative to other cardiac
medications, in particular beta-blocker, for specific cardio-
vascular events. Studies that directly compare these medica-
tions will add to the findings from this meta-analysis. 
Summary written by: Elizabeth A. Jackson, MD 
Persistent Chest Pain and No Obstructive Coronary
Artery Disease
Phan A, Shufelt C, Merz CN.
JAMA 2009;301:1468-1474.
Perspective: The following are 10 points to remember about
persistent chest pain and no obstructive coronary artery dis-
ease (CAD):  
1. An estimated 14-30% of patients undergoing coronary
angiography have no demonstrable CAD; the majority of
these patients are women. 
2. Common causes of noncardiac chest pain include muscu-
loskeletal, pulmonary causes, gastrointestinal causes, and
psychogenic disorder. However, alternative coronary causes,
such as microvascular coronary dysfunction and abnormal
cardiac nociception, should be considered in patients with
chest pain and normal coronary angiographic testing. 
3. An estimated 50% of women with chest pain and no evi-
dence of CAD on angiography have microvascular coronary
dysfunction. The Women’s Ischemia Syndrome Evaluation
(WISE) study observed microvascular dysfunction to be
prevalent among women with persistent chest pain, ischemia
on stress testing, and no obvious CAD on angiography. 
4. Coronary dysfunction increases the risk for adverse cardio-
vascular events including sudden death, myocardial
infarction, and heart failure, with an average 2.5% risk for
events per year. 
5. Coronary vascular autoregulation is usually assessed through
four tests. Coronary flow reserve is indicative of nonendothe-
lial microvascular function. Coronary blood flow is measured
with an intracoronary Doppler flow wire. Change in coronary
artery diameter in response to intracoronary acetylcholine is
indicative of endothelial macrovascular function. Coronary
artery diameter in response to intracoronary nitroglycerin is
indicative of nonendothelial macrovascular function. 
6. Treatment of microvascular coronary dysfunction is
aimed at risk reduction including use of nitrates, beta-
blockers, calcium channel blockers, and statins. 
7. Imipramine can reduce episodes of chest pain in patients
with microvascular dysfunction. 
8. An alternative coronary abnormality observed in patients
with ‘normal coronaries’ and persistent chest pain is abnormal
cardiac nociception.
9. Such patients often have normal coronary arteries, no




Perspective: Overall, these data suggest that hypoglycemia is a
marker of severe illness, rather than a direct cause of adverse
outcomes. The results should be interpreted with caution, as
additional prospective studies are needed to confirm these
findings. For now, clinicians should follow the American
Heart Association recommendations on management of hyper-
glycemia in patients with acute coronary syndrome (Circulation
2008;117:1610-9) and avoid hypoglycemic episodes.
Summary written by: Debabrata Mukherjee, MD 
Effect of Lowering Blood Pressure on Cardiovascular
Events and Mortality in Patients on Dialysis: A
Systematic Review and Meta-Analysis of Randomised
Controlled Trials 
Heerspink HJ, Ninomiya T, Zoungas S, et al. 
Lancet 2009;373:1009-1015. 
Study Question: What is the effect of blood pressure lowering
therapy on patients undergoing dialysis? 
Methods: This meta-analysis and systemic review of randomized
controlled trials of blood pressure lowering in patients on dial-
ysis reported cardiovascular outcomes. Two reviewers extracted
data on patient characteristics, follow-up duration, inclusion
and exclusion criteria, rates of outcome events as well as type
and dose of blood pressure lowering agent, and changes in
blood pressure.
Results: The authors identified eight trials providing data for
1,679 patients and 495 cardiovascular events. Weighted mean
systolic pressure reduction was 4.5 mm Hg, and diastolic pres-
sure reduction was 2.3 mm Hg in treated versus control
patients. There was a reduction in cardiovascular events (rela-
tive risk [RR], 0.71; 95% confidence interval [CI], 0.55-0.92;
p = 0.009), all-cause mortality (RR, 0.80; 95% CI, 0.66-0.96;
p = 0.014), and cardiovascular mortality (RR, 0.71; 95% CI,
0.50-0.99; p = 0.044) associated with blood pressure lowering.
The effect seemed consistent across patient groups and studies.
Conclusions: Treatment with agents to lower blood pressure
should routinely be administered to individuals undergoing
dialysis to reduce cardiovascular morbidity and mortality in
this population.
Perspective: The authors show an extremely consistent and dra-
matic reduction in cardiovascular endpoints associated with
blood pressure reduction for patients on dialysis. These data
suggest that the increased risk of cardiovascular events associ-
ated with dialysis may be amenable to some of the same
methods for reducing risk of cardiovascular events in nondialy-
sis patients, at least for blood pressure reduction. Overall, the
study supports aggressive blood pressure control in patients on
dialysis for renal failure.  
Summary written by: James B. Froehlich, MD 
ischemic changes on stress testing, but persistent chest pain.
Chest pain can be reproduced with infusions of adenosine and
dipyridamole as well as during coronary angiography.
10. No specific guidelines currently exist for the treatment of
abnormal cardiac nociception. However, risk factor manage-
ment is recommended. In addition, imipramine may interact
with pain modulating neurons. Neurostimulation with devices
such as TENS may also reduce chest pain in such patients.
Summary written by: Elizabeth A. Jackson, MD 
Relationship Between Spontaneous and Iatrogenic
Hypoglycemia and Mortality in Patients Hospitalized
With Acute Myocardial Infarction
Kosiborod M, Inzucchi SE, Goyal A, et al.
JAMA 2009;301:1556-1564.
Study Question: What is the mortality risk associated with
hypoglycemic events in patients who develop hypoglycemia
spontaneously and those who develop it as a result of insulin
therapy?
Methods: This retrospective cohort study used data from
Health Facts, a database of patients from 40 U.S. hospitals
between January 1, 2000, and December 31, 2005. Of all
patients in the database, 7,820 were hospitalized with acute
myocardial infarction (AMI) and were hyperglycemic on
admission (glucose level >140 mg/dl). Patients were strati-
fied based on whether they developed a hypoglycemic event
(random glucose level <60 mg/dl) during subsequent hospi-
talization. Logistic regression models were used to evaluate
the association between hypoglycemia and in-hospital mor-
tality within subgroups of patients who were and were not
treated with insulin therapy.
Results: Patients with hypoglycemia were older and had more
comorbidity. Hypoglycemia was associated with increased
mortality in patients not treated with insulin (18.4% [25/136]
mortality in patients with hypoglycemia vs. 9.2% [425/4,639]
in those without hypoglycemia; p < 0.001), but not in those
treated with insulin (10.4% [36/346] mortality in patients with
hypoglycemia vs. 10.2% [276/2,699] in those without hypo-
glycemia; p = 0.92). After multivariable adjustment, there was
a significant interaction between hypoglycemia and insulin
therapy (p value for interaction = 0.01). Hypoglycemia was a
predictor of higher mortality in patients who were not treated
with insulin (odds ratio, 2.32 [95% confidence interval, 1.31-
4.12] vs. patients without hypoglycemia), but not in patients
treated with insulin (odds ratio, 0.92 [95% confidence interval,
0.58-1.45] vs. patients without hypoglycemia).
Conclusions: Although hypoglycemia was associated with
increased mortality in patients with AMI, this risk was con-
fined to patients who developed hypoglycemia spontaneously.
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Association Between Hospital-Reported Leapfrog
Safe Practices Scores and Inpatient Mortality
Kernisan LP, Lee SJ, Boscardin WJ, Landefeld CS, Dudley RA.
JAMA 2009;301:1341-1348. 
Study Question: The Leapfrog Hospital Survey allows hospi-
tals to self-report the steps they have taken toward
implementing the Safe Practices for Better Healthcare
endorsed by the National Quality Forum. What is the rela-
tionship between hospitals’ Safe Practice Score (SPS) and
risk-adjusted inpatient mortality rates?
Methods: The analysis was based on discharge data available
for all urban US hospitals completing the 2006 safe prac-
tices initiative and identifiable in the Nationwide Inpatient
Sample. Leapfrog provided an SPS for each hospital as well
as three alternative scores. Primary outcome was the inpa-
tient risk-adjusted mortality by quartiles of survey score.
Subgroup analyses were performed using data from patients
older than 65 years and patients with 5% or greater expected
mortality risk.
Results: Of 1,075 hospitals completing the 2006 Safe Practices
Survey, 155 (14%) were identifiable in the National Inpatient
Sample (1,772,064 discharges). Raw observed mortality in the
primary sample was 2.09%. Fully adjusted mortality rates by
quartile of SPS, from lowest to highest, were 1.97% (95%
confidence interval [CI], 1.78%-2.18%), 2.04% (95% CI,
1.84%-2.25%), 1.96% (95% CI, 1.77%-2.16%), and 2.00%
(95% CI, 1.80%-2.22%). Results were similar in the subgroup
analyses. None of the three alternative survey scores was asso-
ciated with risk-adjusted inpatient mortality.
Conclusions: In this sample of hospitals that completed the
2006 Safe Practices Survey, survey scores were not signifi-
cantly associated with risk-adjusted inpatient mortality.
Perspective: Leapfrog’s initial recommendations included
adoption of three initiatives that would improve patient
safety: computerized physician order entry, staffing of inten-
sive care units by trained intensivist physicians, and
evidence-based referrals for high-mortality surgeries.
Intuitively, one cannot challenge the value of such recom-
mendations, each of which has been shown to improve
outcome. Yet, in this independent analysis, there was no
predictive value for inpatient mortality. Considering the
findings are based on 155 hospitals and nearly 2 million
patients, one has to question the utility of the Leapfrog
methods and applicability of their public reports. The results
of this study support the concerns expressed by physician
groups who have discouraged public use of quality measures
that have not been fully validated.  
Summary written by: Melvyn Rubenfire, MD
Heart Failure/Transplant
Racial Differences in Incident Heart Failure Among
Young Adults
Bibbins-Domingo K, Pletcher MJ, Lin F, et al.
N Engl J Med 2009;360:1179-1190.
Study Question: What are the antecedents and epidemiology
of heart failure (HF) in young adults?
Methods: The study authors prospectively assessed the inci-
dence of HF over a 20-year period among 5,115 blacks and
whites of both sexes who were 18-30 years of age at base-
line. They used Cox models, to examine predictors of
hospitalization or death from HF. 
Results: Over 20 years, HF developed in 27 participants
(mean [±SD] age at onset, 39 ± 6 years), all but 1 of whom
were black. The cumulative incidence of HF before the age
of 50 years was 1.1% in black women, 0.9% in black men,
0.08% in white women, and 0% in white men (p = 0.001 for
the comparison of black participants and white participants).
Among blacks, independent predictors of HF occurring ~15
years later included higher diastolic blood pressure (hazard
ratio [HR] per 10.0 mm Hg, 2.1; 95% CI, 1.4-3.1), higher
body mass index (HR per 5.7 units, 1.4; 95% CI, 1.0-1.9),
lower high-density lipoprotein cholesterol (HR per 13.3
mg/dl [0.34 mmol/L], 0.6; 95% CI, 0.4-1.0), and kidney
disease (HR, 19.8; 95% CI, 4.5-87.2). Three quarters of
those in whom HF subsequently developed had hyperten-
sion by the time they were 40 years of age. Left ventricular
systolic dysfunction, when the participants were 23-35 years
of age, was independently associated with the development
of HF 10 years, on average, later.
Conclusions: Incident HF before 50 years of age is substan-
tially more common among blacks than among whites.
Hypertension, obesity, and systolic dysfunction that are
present before a person is 35 years of age are important
antecedents that may be targets for the prevention of HF.
Perspective: Studies continue to demonstrate that systemic
blood pressure is a significant risk factor for the develop-
ment of HF (JAMA 1996;275:1557-62). The findings of
this study substantiate the role of systolic blood pressure,
gender, and body mass index in the development of HF,
reported in earlier studies (J Am Coll Cardiol 1999;34:1602-
8). We all need to do a better job in controlling blood
pressure in young adults, particularly blacks, to prevent tar-
get organ damage including strokes, renal disease, and heart
failure.  
Summary written by: Ragavendra R. Baliga, MBBS 





Catheter-Based Renal Sympathetic Denervation for
Resistant Hypertension: A Multicentre Safety and
Proof-of-Principle Cohort Study
Krum H, Schlaich M, Whitbourn R, et al.
Lancet 2009;373:1275-1281.
Study Question: What is the safety and efficacy of catheter-
based renal sympathectomy?
Methods: The authors described a novel technique to treat
hypertension. A catheter was used for radiofrequency abla-
tion of the renal afferent sympathetic fibers that lie adjacent
to and within renal arteries. The 45 patients studied were
followed for 1 year. Primary endpoints were office blood
pressure and safety data before and at 1, 3, 6, 9, and 12
months after the procedure. Renal angiography was done
before, immediately after, and 14-30 days after the proce-
dure, and magnetic resonance angiogram (MRA) 6 months
after the procedure.
Results: The median procedure time (from initiation to com-
pletion of radiofrequency delivery) was 38 minutes. Among
the 45 patients who underwent renal denervation, an average
4.2 denervations were performed in the right renal artery, and
3.7 were performed in the left renal artery. One patient devel-
oped a renal artery dissection (treated with a stent), whereas
another developed a femoral pseudoaneurysm. Renal angiog-
raphy identified focal renal artery irregularities immediately
after radiofrequency energy delivery, but none of them were
flow limiting. Follow-up angiograms in 18 patients at 14-30
days showed no evidence of renal artery stenosis or other
abnormalities. MRAs in 14 treated patients did not show any
irregularities in any treatment locations. The baseline average
office blood pressure was 177/101 mm Hg, (mean 4.7 antihy-
pertensive drugs). Office blood pressures after the procedure
were reduced by -14/-10 at 1 month, -21/-10 at 3 months, 
-22/-11 at 6 months, -24/-11 at 9 months, and -27/-17 mm
Hg at 12 months. A slight increase in blood pressure was
observed in the five nontreated patients.
Conclusions: Catheter-based renal sympathectomy is safe and
is associated with a clinically meaningful sustained reduction
in blood pressure.
Perspective: The investigators are to be commended for devel-
oping a truly novel therapy. The sustained reduction in blood
pressure that was observed in this cohort was impressive, and
if confirmed in larger studies, would make this a major break-
through for the treatment of a difficult clinical problem. I am
rather optimistic that this disruptive device will become widely
used in the near future.  
Summary written by: Hitinder S. Gurm, MBBS 
Noninvasive Cardiology
Cardiac Outcomes After Screening for
Asymptomatic Coronary Artery Disease in Patients
With Type 2 Diabetes: The DIAD Study: A
Randomized Controlled Trial
Young LH, Wackers FJ, Chyun DA, et al., on behalf of the DIAD
Investigators.
JAMA 2009;301:1547-1555.
Study Question: Does routine screening for coronary artery
disease (CAD) identify patients with type 2 diabetes as
being at high cardiac risk, and does it affect their cardiac
outcomes?
Methods: In the DIAD trial, 1,123 participants with type 2
diabetes and no symptoms of CAD were randomly assigned
to be screened with adenosine-stress radionuclide myocar-
dial perfusion imaging (MPI) or not to be screened.
Participants were recruited from diabetes clinics and prac-
tices and prospectively followed up from August 2000 to
September 2007. Primary outcomes included cardiac death
or nonfatal myocardial infarction (MI).
Results: Mean age was 61 years, average diabetes duration
was 9 years, mean glycated hemoglobin was 7.2%, 60% were
male, and 25% were on insulin. The cumulative cardiac
event rate was 2.9% over a mean follow-up of 4.8 years for
an average of 0.6% per year. Seven nonfatal MIs and eight
cardiac deaths (2.7%) occurred among the screened group,
and 10 nonfatal MIs and seven cardiac deaths (3.0%)
among the not-screened group. Of those in the screened
group, 409 participants with normal results and 50 with
small MPI defects had lower event rates than the 33 with
moderate or large MPI defects; 0.4% per year versus 2.4%
per year. Nevertheless, the positive predictive value of hav-
ing moderate or large MPI defects was only 12%. 
Conclusions: In this contemporary study population of
patients with diabetes, the cardiac event rates were low and
were not significantly reduced by MPI screening for
myocardial ischemia over 4.8 years.
Perspective: In these study patients, the average 0.6% fatal
cardiac death and nonfatal MI rate is lower than expected
and helps explain in part why screening for ischemia was of
no value. Screening asymptomatic patients for ischemia who
are otherwise going to be treated as a coronary risk equiva-
lent is not justified. The strategy of screening with a
coronary calcium score, which identifies diabetics with a
higher event rate, to determine intensity of treatment or to
select persons who would benefit from assessing ischemic
burden, needs to be evaluated.  
Summary written by: Melvyn Rubenfire, MD
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Trends in All-Cause and Cardiovascular Disease
Mortality Among Women and Men With and
Without Diabetes Mellitus in the Framingham Heart
Study, 1950 to 2005
Preis SR, Hwang SJ, Coady S, et al.
Circulation 2009;119:1728-1735.
Study Question: Has all-cause mortality declined among
women and men with and without diabetes over time?
Methods: Subjects from the Framingham Heart Study were
used for the present analysis, comparing two time periods:
1950 to 1975 (78,156 person-years), and 1975 to 2005
(79,000 person-years). Subjects ages 45-74 years who com-
pleted at least one serial cohort exam were included. Diabetes
mellitus (DM) was defined as having either a casual glucose
≥200 mg/dl, fasting glucose of ≥126 mg/dl, or treatment for
diabetes. DM status was updated at each 4-year serial cohort
exam. Four-year risk periods were pooled for each individual,
with age and DM status as time-dependent variables. The
primary outcome was all-cause mortality, with secondary out-
comes of cardiovascular and noncardiovascular disease
mortality.
Results: A total of 930 deaths occurred in the first time
period, and 773 deaths occurred in the later time period.
All-cause mortality has declined in recent years among
women without and with DM. A similar pattern was
observed among the men. Women with DM had a threefold
increased risk and men had a twofold increased risk for all-
cause mortality compared to nondiabetics. Cardiovascular
mortality declined over time in women (HR, 0.35; 95% CI,
0.26-0.47 for those with no DM and HR, 0.29; 95% CI,
0.17-0.50 for those with DM) and men (HR, 0.39; 95% CI,
0.31-0.48 for those with no DM and HR, 0.32; 95% CI,
0.21-0.47 for those with DM). Noncardiovascular mortality
also declined among both women without DM, whereas no
change was observed for women with DM or men with or
without DM.
Conclusions: A reduction in all-cause mortality among women
and men with DM was observed over time. However, mor-
tality remains significantly higher among women and men
with DM.
Perspective: DM continues to be a significant risk factor for
mortality in both men and women. Given the high preva-
lence of obesity and DM in this country, efforts to prevent
DM are critical to reducing all-cause and cardiovascular
mortality.  
Summary written by: Elizabeth A. Jackson, MD 
Reduction in C-Reactive Protein and LDL
Cholesterol and Cardiovascular Event Rates After
Initiation of Rosuvastatin: A Prospective Study of
the JUPITER Trial
Ridker PM, Danielson E, Fonseca FA, et al., on behalf of the JUPITER
Trial Study Group.
Lancet 2009;373:1175-1182.
Study Question: Is there additive benefit of lowering both low-
density lipoprotein cholesterol (LDL-C) and high-sensitivity
C-reactive protein (hs-CRP) after the start of statin therapy?
Methods: In an analysis of 15,548 initially healthy men and
women participating in the JUPITER trial (87% of full
cohort), the authors prospectively assessed the effects of
rosuvastatin 20 mg versus placebo on rates of nonfatal
myocardial infarction, nonfatal stroke, admission for unsta-
ble angina, arterial revascularization, or cardiovascular death
(prespecified endpoints) during a maximum follow-up of 5
years, according to on-treatment concentrations of LDL
cholesterol and hs-CRP. All events were included that
occurred after randomization.
Results: Compared with placebo, participants allocated to
rosuvastatin who achieved LDL-C <70 mg/dl had a 55%
reduction in vascular events, and those achieving hs-CRP <2
mg/L, a 62% reduction. Although LDL-C and hs-CRP
reductions were only weakly correlated in individual patients
(r values <0.15), there was a 65% reduction in vascular events
in participants allocated to rosuvastatin who achieved both
LDL-C <70 mg/dl and hs-CRP <2 mg/L versus a 33%
reduction in those who achieved one or neither target. In par-
ticipants who achieved LDL-C <70 mg/dl and hs-CRP <1
mg/L, there was a 79% reduction (event rate 0.24 per 100
person-years; HR, 0.21; 95% CI, 0.09-0.52). Achieved hs-
CRP concentrations were predictive of event rates irrespective
of the lipid endpoint used, including the apolipoprotein (apo)
B and the apo B to apo AI ratio.
Conclusions: For people choosing to start pharmacological pro-
phylaxis, reduction in both LDL cholesterol and hs-CRP are
indicators of successful treatment with rosuvastatin.
Perspective: The pivotal study, JUPITER, has added consider-
ably to the body of evidence that lower is better for both the
LDL-C and hs-CRP, even in healthy persons with an LDL-
C <130 mg/dl and hs-CRP >2 mg/L. This analysis shows
that at very low levels of apo B and the ratio of apo B/apo AI
of <0.4, hs-CRP remains a marker of risk.  
Summary written by: Melvyn Rubenfire, MD 
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